Clinical Trial Update: A Study to Compare the Efficacy, Safety, Immunogenicity, and Pharmacokinetic Profile of HLX13 with YERVOY As a First-Line Treatment for Patients with Unresectable Hepatocellular Carcinoma [Phase 3]

View source ↗

Summary

This is a Phase 3 clinical trial evaluating HLX13 versus YERVOY as first-line therapy for unresectable hepatocellular carcinoma, focusing on efficacy, safety, i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• HLX13
• Yervoy (ipilimumab)

Snippet

Sponsor: Shanghai Henlius Biotech | Conditions: Hepatocellular Carcinoma (HCC) | Phase 3 | Status: NOT_YET_RECRUITING